TISIDB

Summary
Symbol	MCM2
Name	minichromosome maintenance complex component 2
Aliases	D3S3194; KIAA0030; BM28; cdc19; mitotin; CDCL1; minichromosome maintenance deficient (S. cerevisiae) 2 (mito ......
Chromosomal Location	3q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus
Domain	PF00493 MCM2/3/5 family PF12619 Mini-chromosome maintenance protein 2 PF14551 MCM N-terminal domain PF17207 MCM OB domain
Function	Acts as component of the MCM2-7 complex (MCM complex) which is the putative replicative helicase essential for 'once per cell cycle' DNA replication initiation and elongation in eukaryotic cells. The active ATPase sites in the MCM2-7 ring are formed through the interaction surfaces of two neighboring subunits such that a critical structure of a conserved arginine finger motif is provided in trans relative to the ATP-binding site of the Walker A box of the adjacent subunit. The six ATPase active sites, however, are likely to contribute differentially to the complex helicase activity. Required for the entry in S phase and for cell division. Plays a role in terminally differentiated hair cells development of the cochlea and induces cells apoptosis.

> Gene Ontology [ TOP ]
Biological Process	GO:0000082 G1/S transition of mitotic cell cycle GO:0006260 DNA replication GO:0006261 DNA-dependent DNA replication GO:0006268 DNA unwinding involved in DNA replication GO:0006270 DNA replication initiation GO:0006323 DNA packaging GO:0006333 chromatin assembly or disassembly GO:0006334 nucleosome assembly GO:0031497 chromatin assembly GO:0032392 DNA geometric change GO:0032508 DNA duplex unwinding GO:0034728 nucleosome organization GO:0044770 cell cycle phase transition GO:0044772 mitotic cell cycle phase transition GO:0044843 cell cycle G1/S phase transition GO:0065004 protein-DNA complex assembly GO:0070670 response to interleukin-4 GO:0071103 DNA conformation change GO:0071353 cellular response to interleukin-4 GO:0071824 protein-DNA complex subunit organization
Molecular Function	GO:0003678 DNA helicase activity GO:0003688 DNA replication origin binding GO:0004386 helicase activity GO:0042393 histone binding
Cellular Component	GO:0000781 chromosome, telomeric region GO:0000784 nuclear chromosome, telomeric region GO:0000785 chromatin GO:0000808 origin recognition complex GO:0005664 nuclear origin of replication recognition complex GO:0042555 MCM complex GO:0044454 nuclear chromosome part GO:0098687 chromosomal region

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa03030 DNA replication hsa04110 Cell cycle
Reactome	R-HSA-176187: Activation of ATR in response to replication stress R-HSA-68962: Activation of the pre-replicative complex R-HSA-68867: Assembly of the pre-replicative complex R-HSA-1640170: Cell Cycle R-HSA-69620: Cell Cycle Checkpoints R-HSA-69278: Cell Cycle, Mitotic R-HSA-69306: DNA Replication R-HSA-69002: DNA Replication Pre-Initiation R-HSA-69190: DNA strand elongation R-HSA-69206: G1/S Transition R-HSA-69481: G2/M Checkpoints R-HSA-68874: M/G1 Transition R-HSA-453279: Mitotic G1-G1/S phases R-HSA-68949: Orc1 removal from chromatin R-HSA-69304: Regulation of DNA replication R-HSA-69300: Removal of licensing factors from origins R-HSA-69242: S Phase R-HSA-69052: Switching of origins to a post-replicative state R-HSA-69239: Synthesis of DNA R-HSA-176974: Unwinding of DNA

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa03030 DNA replication
hsa04110 Cell cycle

Reactome

R-HSA-176187: Activation of ATR in response to replication stress
R-HSA-68962: Activation of the pre-replicative complex
R-HSA-68867: Assembly of the pre-replicative complex
R-HSA-1640170: Cell Cycle
R-HSA-69620: Cell Cycle Checkpoints
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-69306: DNA Replication
R-HSA-69002: DNA Replication Pre-Initiation
R-HSA-69190: DNA strand elongation
R-HSA-69206: G1/S Transition
R-HSA-69481: G2/M Checkpoints
R-HSA-68874: M/G1 Transition
R-HSA-453279: Mitotic G1-G1/S phases
R-HSA-68949: Orc1 removal from chromatin
R-HSA-69304: Regulation of DNA replication
R-HSA-69300: Removal of licensing factors from origins
R-HSA-69242: S Phase
R-HSA-69052: Switching of origins to a post-replicative state
R-HSA-69239: Synthesis of DNA
R-HSA-176974: Unwinding of DNA

Summary
Symbol	MCM2
Name	minichromosome maintenance complex component 2
Aliases	D3S3194; KIAA0030; BM28; cdc19; mitotin; CDCL1; minichromosome maintenance deficient (S. cerevisiae) 2 (mito ......
Chromosomal Location	3q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between MCM2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	MCM2
Name	minichromosome maintenance complex component 2
Aliases	D3S3194; KIAA0030; BM28; cdc19; mitotin; CDCL1; minichromosome maintenance deficient (S. cerevisiae) 2 (mito ......
Chromosomal Location	3q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of MCM2 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	MCM2
Name	minichromosome maintenance complex component 2
Aliases	D3S3194; KIAA0030; BM28; cdc19; mitotin; CDCL1; minichromosome maintenance deficient (S. cerevisiae) 2 (mito ......
Chromosomal Location	3q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of MCM2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.271	0.427
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.305	0.865
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.251	0.859
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.858	0.0993
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.836	0.644
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.897	0.722
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.141	0.708
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.091	0.951
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.269	0.86
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.452	0.704
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.448	0.798
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.581	2.08e-05

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of MCM2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	9.5	11.8	-2.3	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	18.2	-10.5	0.576
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	0	5.3	0.507
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	MCM2
Name	minichromosome maintenance complex component 2
Aliases	D3S3194; KIAA0030; BM28; cdc19; mitotin; CDCL1; minichromosome maintenance deficient (S. cerevisiae) 2 (mito ......
Chromosomal Location	3q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MCM2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	MCM2
Name	minichromosome maintenance complex component 2
Aliases	D3S3194; KIAA0030; BM28; cdc19; mitotin; CDCL1; minichromosome maintenance deficient (S. cerevisiae) 2 (mito ......
Chromosomal Location	3q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MCM2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MCM2. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	MCM2
Name	minichromosome maintenance complex component 2
Aliases	D3S3194; KIAA0030; BM28; cdc19; mitotin; CDCL1; minichromosome maintenance deficient (S. cerevisiae) 2 (mito ......
Chromosomal Location	3q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MCM2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	MCM2
Name	minichromosome maintenance complex component 2
Aliases	D3S3194; KIAA0030; BM28; cdc19; mitotin; CDCL1; minichromosome maintenance deficient (S. cerevisiae) 2 (mito ......
Chromosomal Location	3q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of MCM2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	MCM2
Name	minichromosome maintenance complex component 2
Aliases	D3S3194; KIAA0030; BM28; cdc19; mitotin; CDCL1; minichromosome maintenance deficient (S. cerevisiae) 2 (mito ......
Chromosomal Location	3q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between MCM2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	MCM2
Name	minichromosome maintenance complex component 2
Aliases	D3S3194; KIAA0030; BM28; cdc19; mitotin; CDCL1; minichromosome maintenance deficient (S. cerevisiae) 2 (mito ......
Chromosomal Location	3q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting MCM2 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse MCM2